iCAD Announces Presentation of New Clinical Data on Xoft System for Treatment of Nonmelanoma Skin Cancer and Early-Stage Breast Cancer at ASTRO 2017

Company will also host in-booth expert presentations and active peer-to-peer learning opportunities to review optimal strategies to improve outcomes in patient care using the Xoft System

NASHUA, NH and SAN DIEGO, CA (Booth #3139) – September 25, 2017 – iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that external researchers will present new clinical data supporting the use of the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® for the treatment of nonmelanoma skin cancer (NMSC) and early-stage breast cancer during the 2017 American Society for Radiation Oncology (ASTRO) meeting at the San Diego Convention Center in San Diego, CA from September 24-27. iCAD will also host additional presentations and a series of peer-to-peer discussion opportunities with leading eBx experts at its booth (#3139).

“We look forward to the presentation of these compelling new clinical data by leading external researchers that significantly reinforce the benefits that the Xoft System delivers to patients and physicians in the treatment of both early-stage breast cancer and nonmelanoma skin cancer,” said Ken Ferry, CEO of iCAD. “Our technology is proven to be safe and effective in appropriate patients, while offering the opportunity to treat a range of cancers using one versatile, integrated system. iCAD remains committed to providing innovative, leading-edge radiation therapies that empower physicians with full confidence to precisely and effectively treat cancer.”

In an oral presentation, Rakesh Patel, MD, radiation oncologist at Precision Cancer Specialists, will review results from a study published in the Journal of Contemporary Brachytherapy comparing the use of the Xoft System and Mohs micrographic surgery for the treatment of NMSC.

“While Mohs surgery is considered the standard of care for NMSC, Xoft skin eBx represents an important option for many patients that can target the radiation dose directly to the cancerous site in a painless, non-invasive procedure,” said Dr. Patel. “We are excited to present these data, which add to a growing body of evidence indicating that eBx offers comparable results to Mohs surgery in appropriately selected early-stage NMSC patients.”

Nicholas Flores, MD, director of radiation oncology at Arizona Dermatology, will also present data from a study of the treatment of peri-ocular NMSC using the Xoft System. From 2013 to 2016, Dr. Flores and fellow researchers treated 86 patients with basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) of the eyelid with Xoft skin eBx. Results showed a 99 percent local control rate at two years post-treatment and no reported cases of side effects, such as long-term vision changes, dry eye, corneal injury, or retinitis.

Alam M. Nisar Syed, medical director, radiation oncology & endocurietherapy, MemorialCare Cancer Institute, Long Beach Memorial Medical Center, will also present data on the use of intraoperative radiation therapy (IORT) with the Xoft System in early-stage breast cancer patients. Dr. Syed will discuss a non-randomized, prospective, multi-center trial that involved 1,076 patients with ductal carcinoma in situ (DCIS) or invasive ductal carcinoma who met specific selection criteria and received lumpectomy followed by IORT with the Xoft System. Results showed that Xoft IORT deliver low morbidity, excellent to
good cosmetic results and a low rate of high-grade adverse events and recurrences in appropriate patients.

The details of all iCAD oral and poster presentations during ASTRO are as follows:

**Oral Presentations:**

**Title:** Comparison of Electronic Brachytherapy and Mohs Micrographic Surgery – A Matched Pair Cohort Study for Treatment of Non-Melanoma Skin Cancer  
**Author:** Rakesh Patel, MD, Precision Cancer Specialists  
**Date:** Wednesday, September 27  
**Time:** 7:45-9:00 am PST  
**Room Number:** 3  
**Presentation Number:** 263

**Title:** Self-reported Quality of Life in Early-stage Breast Cancer: An Ongoing Multicenter Trial of Intraoperative Electronic Brachytherapy During Breast Conservation Surgery  
**Author:** Alam M. Nisar Syed, MD, MemorialCare Cancer Institute, Long Beach Memorial Medical Center  
**Date:** Monday, September 25  
**Time:** 7:45-9:00 am PST  
**Room Number:** 5B  
**Presentation Number:** 87

**Poster Presentations:**

**Title:** Electronic Brachytherapy at the Time of Breast Conservation Surgery for Early-Stage Breast Cancer: Early Follow-up Results of a Non-randomized, Multicenter Trial  
**Author:** Alam M. Nisar Syed, MD, MemorialCare Cancer Institute, Long Beach Memorial Medical Center  
**Date:** Monday, September 25  
**Time:** 10:45-12:15 pm PST  
**Location:** Poster Hall  
**Poster Number:** 2116

**Title:** Peri-ocular non-melanoma skin cancers: Outcome in 86 cases treated with High Dose Rate Electronic Brachytherapy  
**Author:** Nicholas Flores, MD, Arizona Dermatology  
**Date:** Tuesday, September 26  
**Time:** 2:45-4:15 pm PST  
**Location:** Poster Hall  
**Poster Number:** 2800

iCAD will also host a series of expert presentations and peer-to-peer learning opportunities in the Xoft booth (#3139) throughout the meeting. For further information, please visit [http://www.xoftinc.com/astro2017.html](http://www.xoftinc.com/astro2017.html).

**About Xoft Axxent Electronic Brachytherapy System**

The Xoft System is an isotope-free radiation treatment that is FDA cleared, CE marked, and licensed in a growing number of countries for the treatment of cancer anywhere in the body, including treatment of
early-stage breast cancer, gynecological cancers and non-melanoma skin cancer. It utilizes a proprietary miniaturized x-ray as the radiation source that delivers precise treatment directly to cancerous areas while sparing healthy tissue and organs. The Xoft System requires only minimal shielding and therefore does not require room redesign or construction investment. Minimal shielding also allows medical personnel to remain in the room with the patient during treatment. The mobility of the Xoft System makes it easy to treat patients at multiple locations and to easily store the system when not in use. The Axxent Hub is a cloud-based oncology collaboration software solution that enables centers to monitor treatment workflow and enhance communication between clinical specialists. Xoft is a wholly owned subsidiary of iCAD, Inc. For more information about Xoft visit www.xoftinc.com, like us on Facebook or follow us on Twitter at @xofticad.

About iCAD, Inc.

iCAD delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier and faster while improving patient outcomes. iCAD offers a comprehensive range of upgradeable computer aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast, prostate and colorectal cancers. iCAD’s Xoft® Axxent® Electronic Brachytherapy (eBx®) System® delivers high dose rate, low energy radiation, which targets cancer while minimizing exposure to surrounding healthy tissue. The Xoft System is FDA cleared and CE marked for use anywhere in the body, including treatment of non-melanoma skin cancer, early-stage breast cancer and gynecological cancers. The comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection and radiation therapy treatments. For more information, visit or www.icadmed.com or www.xoftinc.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to the Company’s ability to defend itself in litigation matters, to achieve business and strategic objectives, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “would”, “could”, “consider”, “project”, “estimate”, “will”, “continue”, “anticipate”, “likely”, “seek”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained

**Contact:**

For iCAD investor relations:

LifeSci Advisors  
Bob Yedid, (646)-597-6989  
Bob@lifesciadvisors.com

or

For iCAD media inquiries:

Berry & Company Public Relations, LLC  
Lynn Granito, 212-253-8881  
lgranito@berrypr.com